These doctor-patient conversations had been labeled “death panels” by opponents of the Affordable Care Act. Meanwhile, in a bid to reduce backlogs, Medicare offers a deal to hospitals to pay 68 percent of short-term stay medical claims that were reject…
Uncategorized
Ocular Therapeutix announces Q2 financial results
Ocular Therapeutix has announced its second-quarter financial results, which included a net loss attributable to common stockholders of approximately $6.4 million, or $2.10 per share, compared with $3.1 million, or $1.19 per share, during the same time…
Uncategorized
Fenofibrate slows diabetic retinopathy progression in at-risk patients
Intensive treatment of glycemia and dyslipidemia slowed the progression of diabetic retinopathy in diabetic patients with cardiovascular disease or associated risk factors, according to study findings.Data were culled from the Action to Control Cardiov…
Uncategorized
Allergan responds to Valeant, Pershing Square counterclaims
Allergan has filed an answer in the U.S. District Court for the Central District of California in response to Valeant Pharmaceuticals and Pershing Square Capital Management counterclaims, according to an Allergan press release.The response addresses counterclaims from Valeant and Pershing Square regarding Allergan’s previous statements on the unsustainability of Valeant’s underlying business model, according to the release.
Uncategorized
Ozurdex approved in EU for treatment of DME
The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press release.Under the marketing authorization extension, the dexamethasone 0.7 mg intra…
Study to measure and estimate global ablation market
Reportbuyer.com has added a new market research report: Ablation Devices: Technologies and Global Markets.